- CINNOLINE COMPOUNDS AND FOR THE TREATMENT OF HPK1-DEPENDENT DISORDERS SUCH AS CANCER
-
Cinnoline compounds of formula (I), variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods
- -
-
Paragraph 0325
(2020/05/12)
-
- NAPHTHYRIDINES AS INHIBITORS OF HPK1
-
Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
- -
-
Paragraph 0776; 0777
(2018/10/21)
-
- HETEROARYLOXYHETEROCYCLYL COMPOUNDS AS PDE10 INHIBITORS
-
Heteroaryloxyheterocyclyl compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, Huntington's Disease, bipolar disorder, obsessive-compulsive disorder, and the like.
- -
-
Page/Page column 83
(2011/12/02)
-
- PHOSPHODIESTERASE 4 INHIBITORS
-
PDE4 inhibition is achieved by novel compounds of the Formula (I) wherein R1 and R2 are as defined herein.
- -
-
-